HUP0101501A3 - Fap alpha-specific antibody with improved producibility - Google Patents

Fap alpha-specific antibody with improved producibility

Info

Publication number
HUP0101501A3
HUP0101501A3 HU0101501A HUP0101501A HUP0101501A3 HU P0101501 A3 HUP0101501 A3 HU P0101501A3 HU 0101501 A HU0101501 A HU 0101501A HU P0101501 A HUP0101501 A HU P0101501A HU P0101501 A3 HUP0101501 A3 HU P0101501A3
Authority
HU
Hungary
Prior art keywords
specific antibody
fap alpha
improved producibility
producibility
improved
Prior art date
Application number
HU0101501A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUP0101501A2 publication Critical patent/HUP0101501A2/hu
Publication of HUP0101501A3 publication Critical patent/HUP0101501A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HU0101501A 1998-04-30 1999-04-22 Fap alpha-specific antibody with improved producibility HUP0101501A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107925A EP0953639A1 (en) 1998-04-30 1998-04-30 FAPalpha-specific antibody with improved producibility
PCT/EP1999/002711 WO1999057151A2 (en) 1998-04-30 1999-04-22 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY

Publications (2)

Publication Number Publication Date
HUP0101501A2 HUP0101501A2 (hu) 2001-08-28
HUP0101501A3 true HUP0101501A3 (en) 2004-01-28

Family

ID=8231860

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101501A HUP0101501A3 (en) 1998-04-30 1999-04-22 Fap alpha-specific antibody with improved producibility

Country Status (27)

Country Link
EP (2) EP0953639A1 (enExample)
JP (1) JP4421779B2 (enExample)
KR (1) KR100580936B1 (enExample)
CN (1) CN1303430A (enExample)
AR (1) AR016243A1 (enExample)
AT (1) ATE356873T1 (enExample)
AU (1) AU760305B2 (enExample)
BG (1) BG65034B1 (enExample)
BR (1) BR9910577A (enExample)
CA (1) CA2327586C (enExample)
CO (1) CO5050255A1 (enExample)
DE (1) DE69935516T2 (enExample)
EA (1) EA005401B1 (enExample)
EE (1) EE200000642A (enExample)
ES (1) ES2283114T3 (enExample)
HU (1) HUP0101501A3 (enExample)
ID (1) ID26555A (enExample)
IL (1) IL138701A0 (enExample)
NO (1) NO20005412L (enExample)
NZ (1) NZ508456A (enExample)
PL (1) PL358087A1 (enExample)
SK (1) SK16192000A3 (enExample)
TR (1) TR200003181T2 (enExample)
UA (1) UA73276C2 (enExample)
WO (1) WO1999057151A2 (enExample)
YU (1) YU66300A (enExample)
ZA (1) ZA200005506B (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2401252A1 (en) * 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
WO2004001004A2 (en) * 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
JP4459810B2 (ja) * 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EA200700469A1 (ru) * 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
US7521542B2 (en) 2004-05-10 2009-04-21 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CA2675233A1 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
EA022990B1 (ru) * 2007-08-20 2016-04-29 Глаксо Груп Лимитед Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок
ATE524740T1 (de) * 2007-12-10 2011-09-15 Hoffmann La Roche Seprase als krebsmarker
CA2701970A1 (en) * 2007-12-10 2009-06-18 F. Hoffmann-La Roche Ag Marker panel for colorectal cancer
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
US8557239B2 (en) 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
HUE036077T2 (hu) * 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
CA2810359C (en) 2010-09-09 2021-06-22 Pfizer Inc. 4-1bb binding molecules
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
LT3653644T (lt) * 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
CA3011455A1 (en) * 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
CN110526991A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN110526979A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109053893B (zh) * 2018-08-15 2021-03-30 智享生物(苏州)有限公司 一种抗d-二聚体单克隆抗体及其制备方法
CN112972675A (zh) * 2018-09-07 2021-06-18 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP3997104A1 (en) 2019-07-08 2022-05-18 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
IL289675B1 (en) 2019-07-08 2025-09-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and their use
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
US12371491B2 (en) 2019-09-03 2025-07-29 Bio-Thera Solutions, Ltd. Anti-TIGIT immunosuppressant and application thereof
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
US20230174649A1 (en) * 2020-04-30 2023-06-08 I-Mab Biopharma Us Limited Pharmaceutical compositions containing anti-cd47 antibodies
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
KR102799318B1 (ko) * 2020-08-11 2025-04-23 주식회사 카나프테라퓨틱스 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022205523A1 (en) 2021-01-07 2023-07-13 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
WO2023031644A1 (en) 2021-08-31 2023-03-09 Full-Life Technologies Limited Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
JP2025503533A (ja) * 2021-12-30 2025-02-04 コンセプト トゥー メディシン バイオテック カンパニー， リミテッド Ｆａｐ－アルファに対するヒト抗体
CN119604540A (zh) * 2022-08-03 2025-03-11 南京维立志博生物科技股份有限公司 靶向FAP和TGFβ的抗体融合蛋白及其用途
CN120112308A (zh) 2022-10-07 2025-06-06 吉尼松公司 使用抗fap car-t细胞免疫治疗骨骼肌病
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN120309735A (zh) * 2024-01-15 2025-07-15 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN118496382B (zh) * 2024-05-22 2025-01-07 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
CN119265201A (zh) * 2024-08-23 2025-01-07 中国人民解放军海军军医大学第一附属医院 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU2782292A (en) * 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
ZA936260B (en) * 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AU716257B2 (en) * 1996-05-01 2000-02-24 Genitope Corporation Vaccines for treatment of lymphoma and leukemia

Also Published As

Publication number Publication date
SK16192000A3 (sk) 2001-04-09
EP1098979A2 (en) 2001-05-16
JP4421779B2 (ja) 2010-02-24
CA2327586C (en) 2013-02-26
WO1999057151A2 (en) 1999-11-11
YU66300A (sh) 2004-03-12
KR100580936B1 (ko) 2006-05-17
ID26555A (id) 2001-01-18
CA2327586A1 (en) 1999-11-11
DE69935516D1 (de) 2007-04-26
ZA200005506B (en) 2002-05-14
EP1098979B1 (en) 2007-03-14
IL138701A0 (en) 2001-10-31
ES2283114T3 (es) 2007-10-16
NZ508456A (en) 2004-03-26
AU4032299A (en) 1999-11-23
AR016243A1 (es) 2001-06-20
UA73276C2 (en) 2005-07-15
BG104828A (en) 2001-09-28
KR20010042826A (ko) 2001-05-25
EE200000642A (et) 2002-04-15
EA005401B1 (ru) 2005-02-24
DE69935516T2 (de) 2008-01-31
EA200001023A1 (ru) 2001-06-25
WO1999057151A3 (en) 2000-03-16
HUP0101501A2 (hu) 2001-08-28
CO5050255A1 (es) 2001-06-27
BG65034B1 (bg) 2006-12-29
NO20005412L (no) 2000-12-06
BR9910577A (pt) 2001-09-11
EP0953639A1 (en) 1999-11-03
CN1303430A (zh) 2001-07-11
NO20005412D0 (no) 2000-10-27
TR200003181T2 (tr) 2001-04-20
ATE356873T1 (de) 2007-04-15
AU760305B2 (en) 2003-05-15
PL358087A1 (en) 2004-08-09
JP2002513556A (ja) 2002-05-14

Similar Documents

Publication Publication Date Title
HUP0101501A3 (en) Fap alpha-specific antibody with improved producibility
GB9809839D0 (en) Antibody
EP1073464A4 (en) MONOCLONAL ANTIBODIES WITH REDUCED IMMUNIZABILITY
DE59808176D1 (de) Kraftstofffördereinrichtung
IT1306854B1 (it) Autoveicolo con capote apribile.
PL333742A1 (en) Compression -ignition engine
GB9818915D0 (en) Antibodies
GB9826730D0 (en) An engine
GB9828700D0 (en) Antibody
GB9819411D0 (en) Antibodies
GB2342394B (en) Engine
GB9723781D0 (en) Latches
GB9800760D0 (en) Antigens
GB9816327D0 (en) Antibody
DE59908352D1 (de) Kraftstoffilter
HU9800226V0 (en) Lock with increasing closingnumber
TW338914U (en) Latches
HU1601U (en) Chopping-board with collector
TW475757U (en) Scanner structure
GB9816280D0 (en) Antibody combination
TW376957U (en) Improved structure for the engine
GB9818923D0 (en) Burnerless combustion
GB2333365B (en) Exhaust probe assembly
HU1694U (en) Pile-wall structure with end-tenon
AU132364S (en) Gate latch

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees